Brokers Set Expectations for Shattuck Labs Q1 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for Shattuck Labs in a report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.18) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.88) EPS and FY2028 earnings at ($1.04) EPS.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The business had revenue of ($1.00) million during the quarter, compared to analysts’ expectations of $0.17 million.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Citigroup lifted their price objective on Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 6th. Wedbush upped their target price on shares of Shattuck Labs from $4.00 to $8.00 and gave the company an “outperform” rating in a report on Friday, March 6th. TD Cowen restated a “buy” rating on shares of Shattuck Labs in a report on Friday. Finally, Piper Sandler began coverage on shares of Shattuck Labs in a report on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.00.

Shattuck Labs Stock Performance

Shattuck Labs stock opened at $5.96 on Monday. The company has a market cap of $426.50 million, a P/E ratio of -7.74 and a beta of 1.55. Shattuck Labs has a one year low of $0.69 and a one year high of $6.25. The business has a fifty day moving average of $4.27 and a two-hundred day moving average of $2.93.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Shattuck Labs during the third quarter worth approximately $29,000. Virtu Financial LLC bought a new position in Shattuck Labs during the third quarter valued at about $38,000. AQR Capital Management LLC grew its stake in shares of Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Shattuck Labs in the second quarter worth approximately $44,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Shattuck Labs in the 3rd quarter worth $46,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.